- Report
- August 2022
- 83 Pages
Global
From €4588EUR$4,750USD£3,926GBP
- Report
- January 2022
- 200 Pages
Global
From €7244EUR$7,500USD£6,199GBP
- Report
- January 2022
- 60 Pages
Global
From €3815EUR$3,950USD£3,265GBP
- Report
- January 2022
- 200 Pages
Global
From €7244EUR$7,500USD£6,199GBP
- Report
- January 2022
- 60 Pages
Global
From €3815EUR$3,950USD£3,265GBP
- Report
- August 2022
- 120 Pages
Global
From €4346EUR$4,500USD£3,719GBP
- Report
- August 2022
- 116 Pages
Global
From €4346EUR$4,500USD£3,719GBP
- Report
- November 2019
- 115 Pages
Global
From €4298EUR$4,450USD£3,678GBP
- Report
- March 2023
- 161 Pages
Global
From €2415EUR$2,500USD£2,066GBP
- Report
- February 2021
Global
From €2859EUR$2,960USD£2,446GBP
- Report
- November 2021
- 620 Pages
Global
From €3863EUR$4,000USD£3,306GBP
- Report
- September 2019
Global
From €5186EUR$5,370USD£4,438GBP
- Report
- September 2019
Global
From €5186EUR$5,370USD£4,438GBP
- Report
- March 2023
- 147 Pages
Global
From €5794EUR$5,999USD£4,958GBP
The Human Papillomavirus (HPV) Drug market is a subset of the Infectious Diseases Drugs market. HPV is a virus that can cause a range of health issues, including genital warts and certain types of cancer. HPV drugs are used to treat and prevent these conditions. HPV drugs are typically administered as a vaccine, which helps to prevent the virus from spreading. In addition, there are drugs available to treat existing HPV infections. These drugs are typically administered orally or topically.
The HPV Drug market is highly competitive, with a number of companies offering products. Some of the major players in the market include Merck, GlaxoSmithKline, Sanofi, Pfizer, and Novartis. These companies offer a range of HPV drugs, including vaccines and treatments. Show Less Read more
